The Rainwater Charitable Foundation

Fort Worth’s population is booming, but affordable housing isn’t keeping up. With a shortage of over 85,000 homes in DFW, we’re working to bring innovative solutions to help families find stability. Check out our latest blog to learn more about the challenges and our work to find solutions to affordable housing. https://lnkd.in/g_VkdcKF

As sponsors of CurePSP’s #Neuro2024 in Toronto, we’re looking forward to the sessions our team will be moderating and participating in this week! Amy Rommel, Ph.D. will chair a conversation exploring therapeutic targets while Glenn A. Harris will lead a focused discussion on biomarkers and PET for tauopathies and appear as a panelist to speak about derisking biomarker and therapeutic development for PSP.    Explore the agenda and learn more about the symposium: https://lnkd.in/ePGxJqm6

Our goal for the #TauConsortium is to foster collaboration between world-class researchers to help treat and prevent primary tauopathies. We engage researchers to help us turn that goal into a reality.     A recent example of this collaboration in action is the Consortium members’ contribution to a PET radiotracer trial in healthy adult patients, featured in this Nature Portfolio publication: https://lnkd.in/eTTFz-MA

Tauopathy Challenge Workshop awardee Dr. Rik van der Kant is examining if cholesterol or other lipids contribute to the tau pathology in progressive supranuclear palsy or frontotemporal dementias. His research hopes to provide a clearer understanding of the early processes that drive these conditions.    Learn more about Dr. van der Kant’s research here: https://lnkd.in/eaEtG4fZ

New Heights Education, North Texas' first-ever adult high school, celebrated its grand opening in the Stop Six Neighborhood of #FortWorth. The event included the presence and public comment from key community leaders, the inaugural incoming class of students, and elected officials. But why all the fanfare about a high school launch? With flexible schedules and no cost to students, this school is breaking barriers to better jobs and opportunities for adults to earn both a diploma and career certifications. Learn more about how RCF is partnering with this innovative school to demonstrate how collaboration can take students, despite their age, to New Heights: https://lnkd.in/gx7xRmFk

Members of our #TauConsortium recently contributed to a Nature Portfolio publication which set the foundation for a PET radiotracer trial in healthy adult patients.      Learn more about how we support PET imaging through our medical research program to help improve its sensitivity and selectivity to identify different forms of tau through radiochemistry: https://lnkd.in/eTTFz-MA

Last month, we had the pleasure of hosting our #TauConsortium investigators meeting (TCIM). The event kicked off with a patient-focused spotlight on ReDLat Dementia, a multi-partner initiative expanding dementia research in Latin America, and included an awe-inspiring session narrated by both Dr. Juliana Acosta-Uribe and documentary photographer Alex Kornhuber showcasing the lived experiences of dementia patients and their families.  Science can be competitive and isolating, but our TCIM is a powerful reminder that collaboration is essential to advance research into primary tauopathies.    Read more about this year’s program: https://lnkd.in/etaG-QBw

We’re always searching for ways to help advance neurodegenerative research, such as CurePSP’s Pathway and Pipeline Grant Program. This program encourages researchers’ pursuit of new ideas that will help further our understanding of primary tauopathies by supporting the production of pilot studies that can eventually qualify for larger grants. It’s our hope that our contribution will help investigators explore their potentially groundbreaking ideas.    Learn more and apply for the program before October 3: https://lnkd.in/ebzrc7_Z

We convened a group of 35 experts in neurodegenerative research to implement a framework that may guide the translation of tauopathy therapeutics from discovery to early-phase clinical trials. With Howard Feldman leading the charge, experts applied the “5 Rights” of precision drug development in Alzheimer’s Disease to advise on how to de-risk common challenges and increase the likelihood of successful trials for critically needed new treatments for tauopathies. Explore the collaboration across industry, academia and non-profit organizations in the Alzheimer's Association®’s Alzheimer’s & Dementia Journal (open access): https://lnkd.in/exZWzf_A   The Right Target  The Right Drug  The Right Biomarker  The Right Participants  The Right Trial 

As part of our work to advance neurodegenerative research, we’re excited to expand our partnership with CurePSP to support their Pathway and Pipeline Grant Program with a $200,000 contribution. We look forward to the program’s scientific impact as early-career researchers pursue potential cures for tauopathies including PSP and CBD.